KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBITDA (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EBITDA for 15 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 104.37% year-over-year to $2.6 million, compared with a TTM value of -$26.7 million through Dec 2025, up 91.67%, and an annual FY2025 reading of -$26.7 million, up 91.67% over the prior year.
  • EBITDA was $2.6 million for Q4 2025 at Travere Therapeutics, down from $25.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $150.9 million in Q3 2023 and bottomed at -$136.5 million in Q1 2024.
  • Average EBITDA over 5 years is -$45.9 million, with a median of -$56.8 million recorded in 2024.
  • The sharpest move saw EBITDA crashed 3653.67% in 2021, then soared 321.09% in 2023.
  • Year by year, EBITDA stood at -$51.6 million in 2021, then plummeted by 33.76% to -$69.0 million in 2022, then decreased by 27.44% to -$88.0 million in 2023, then surged by 32.56% to -$59.3 million in 2024, then soared by 104.37% to $2.6 million in 2025.
  • Business Quant data shows EBITDA for TVTX at $2.6 million in Q4 2025, $25.5 million in Q3 2025, and -$12.7 million in Q2 2025.